Your browser doesn't support javascript.
loading
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
Harada, Yohei; Sato, Akemi; Nakamura, Hideaki; Kai, Keita; Kitamura, Sho; Nakamura, Tomomi; Kurihara, Yuki; Ikeda, Sadakatsu; Sueoka, Eisaburo; Kimura, Shinya; Sueoka-Aragane, Naoko.
Affiliation
  • Harada Y; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Sato A; Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Nakamura H; Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Kai K; Department of Transfusion Medicine, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Kitamura S; Department of Pathology, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Nakamura T; Department of Pathology, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Kurihara Y; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Ikeda S; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Sueoka E; Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
  • Kimura S; Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
  • Sueoka-Aragane N; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
BMC Cancer ; 23(1): 77, 2023 Jan 23.
Article de En | MEDLINE | ID: mdl-36690964
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni